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Introduction: Biological clocks even present in immortalized cell lines, regulate 
physiological processes in a time-dependent manner, driving transcriptional and 
metabolic rhythms. The disruption of circadian rhythmicity in modern life (shiftwork, 
jetlag, etc.) may promote higher cancer risk and metabolic disorders. We have 
previously demonstrated that glycerophospholipid (GPL) synthesis is highly regulated 
by the biological clock under physiological conditions in retinal cells (Guido et al 2001, 
Garbarino-Pico et al 2004, 2005), in the mice liver (Gorne et al 2014), and in fibroblast 
(NIH3T3 cells) cultures (Marquez et al 2004, Acosta et al 2013). Significant temporal 
changes were observed in GPL labeling in different cells studied as well as in GPL 
synthesizing enzyme expression and activity while rhythms were lost after the clock 
protein PER1 knocked down. The molecular clock drives the expression of activators 
(BMAL1), repressors (PER1, 2, REV-ERB) and clock-controlled genes (Choline 
Kinase, etc.) along the 24 h. Nevertheless, little is known about the biological clock 
function in tumor cells and how its pharmacological modulation could offer selective 
anticancer strategies. REV-ERBs are circadian repressor components involved in 
tumorigenesis (metabolism, proliferation and inflammation). SR9009 is a synthetic 
REV-ERB specific agonist exhibiting potent in vivo activity on metabolism and cell 
viability.  Objectives: Here we investigated metabolic rhythms in two human tumor cell 
lines: the glioblastoma T98G and hepatocarcinoma HepG2 cells. Also, we evaluated 
whether cells displayed differential time responses to chemotherapy after treatment with 
bortezomib (BOR) or SR9009. Methods: T98G and HepG2 cells grown in 10% FBS-
DMEM were synchronized with 100 nM Dexamethasone (DEX) for 20 min and 
collected at different times. Cell viability was analyzed by MTT assay at 570 nm after 
SR9009 (20 µM) or BOR (500 nM). Reactive oxygen species levels (ROS) were 
determined with 2,7-dichlorodihydrofluorescein diacetate (2 μM). Lipid droplets (LDs) 
were stained with Nile Red (1.5 µg/ml) and visualized by confocal microscopy and flow 
cytometry. Results: In synchronized T98G cells, rhythms of redox state and GPL 
metabolisms were observed while cell viability significantly changed over time after 
BOR or SR9009 treatment. Moreover, the temporal changes in susceptibility and the 
redox cycles were further altered after Bmal1 knock-down, indicating a cross-talk 
between the molecular clock and the metabolic oscillators. SR9009 treated cells 
exhibited significant anti proliferative effects and displayed differential time responses 
to the treatment. SR9009 treatment decreased ROS levels while BOR increased them. 
However, both treatments significantly increased LD levels whereas the combined 
treatment significantly decreased cell viability. Synchronized HepG2 cells displayed 
significant circadian rhythms in the expression of Bmal1, PER1, Rev-Erb and ChoK-
like proteins, in the content of endogenous GPLs (PC and PE) and in LD levels (number 
and size). Remarkably, when the circadian clock was perturbed by knocking down 
Bmal1, LD levels were severely affected and rhythms damped out. Conclusions: Results 
suggest that an intrinsic metabolic clock continues to function in diverse proliferating 
tumor cells and the pharmacological modulation of their intrinsic clock severely 
affected tumor cell metabolism and promote anti proliferative effects.  
 
